AstraZeneca PLC
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
AstraZeneca PLC has 69 disclosed EU lobbying meetings from 2024-10-01 to 2026-06-29: 17 with the European Commission and 52 with Members of the European Parliament. Source: EU Transparency Register no. 249402638316-62, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2026-03-24- Category
- Companies & groups
- Legal status
- Public Limited Company
- Declared lobbying cost
- €800,000
- Lobbying FTEs
- 4.35
- Members
- 5
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Business and industry · Climate action · Consumers · Digital economy and society · Economy, finance and the euro · Education and training · Employment and social affairs · Environment · Foreign affairs and security policy · International co-operation and development · Public health · Research and innovation
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Laszlo Kristoffy3
- Patricia Reilly2
- Jana Dabbelt1
- Paulina Dejmek Hack1
- Jessika Roswall1
Disclosed meetings
Newest first, showing the most recent 60 of 69. EC = European Commission, EP = Member of the European Parliament.
- availability of medicinessource ↗
- Biotech Actsource ↗
- EU Biotech Actsource ↗
- 2026-05-06ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth packagesource ↗
- Biotech Actsource ↗
- 2026-04-28ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiEUCOPE - Strasbourgsource ↗
- Biotech actsource ↗
- 2026-03-31ECPaulina Dejmek Hack · Cabinet of Commissioner Jessika RoswallSustainable technologiessource ↗
- Biotech Actsource ↗
- EU Biotech Act Isource ↗
- 2026-03-12ECJessika Roswall · Cabinet of Commissioner Jessika RoswallDiscussion on innovation in Europe. And exchange of views on the topic PFAS.source ↗
- 2026-03-05ECPatricia Reilly · Cabinet of President Ursula von der LeyenExchange on EU health and industrial policiessource ↗
- Health Policysource ↗
- Biotechsource ↗
- Health Policysource ↗
- Biotech Act 1source ↗
- 2026-02-03ECCarmen Laplaza Santos · Head of UnitExchange of views on the competitiveness of the European pharmaceutical sector.source ↗
- 2026-01-21ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth Packagesource ↗
- 2025-12-03ECUlla Schwager · Head of UnitExchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sectorsource ↗
- Pharmaceutical legislationsource ↗
- 2025-11-18ECSaila Rinne · Head of UnitAI in health.source ↗
- 2025-10-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičUS and EU trade relations in the context of the pharmaceutical sectorsource ↗
- Current health situation in the EUsource ↗
- Clinical trials policysource ↗
- 2025-09-04ECRainer Becker · DirectorExchange of views on multinational clinical trials in the context of the upcoming Biotech Actsource ↗
- Health policysource ↗
- CMAsource ↗
- 2025-07-14ECPatricia Reilly · Cabinet of President Ursula von der LeyenCompetitiveness of the biopharmaceutical sectorsource ↗
- Critical Medicines Actsource ↗
- SANTsource ↗
- Meeting CMAsource ↗
- Critical medicinessource ↗
- Competitividad del sectorsource ↗
- Patient rightssource ↗
- Health policysource ↗
- Introductory meetingsource ↗
- PFASsource ↗
- 2025-04-23ECVilija Sysaite · Cabinet of Executive Vice-President Stéphane SéjournéTrade, simplification, IPsource ↗
- 2025-03-28ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiDiscussion about EU priorities in the area of public health.source ↗
- 2025-03-24ECIvan Dimov · Cabinet of Commissioner Ekaterina ZaharievaLife Sciences Strategysource ↗
- 2025-03-24ECVita Jukne · Cabinet of Commissioner Jessika RoswallThe climate-health nexus, Urban Wastewater Treatment Directive and PFAS restrictionsource ↗
- Medicinessource ↗
- Pharmaceutical strategysource ↗
- Medcicinessource ↗
- Health policysource ↗
- Ongoing negotations on GPLsource ↗
- Competitiveness of the pharmaceutical sector in Europesource ↗
- 2025-01-22ECIoan-Dragos Tudorache · Cabinet of Executive Vice-President Stéphane SéjournéEconomic state of Play of pharmaceutical sectorsource ↗
- Pharmasource ↗
- ENVIsource ↗
- Health policy, medicinessource ↗
- Sustainable industrial practices and marketing issuessource ↗
- Gesundheitspolitische Agenda in der EU - Prioritäten für die neue Legislaturperiodesource ↗
- Health policysource ↗
- Priorities for the new mandate on healthsource ↗
- Priorities for the mandatesource ↗
- EU Chemical Policysource ↗
- Lääkemarkkinoiden sääntelysource ↗
- Competitividad del sector farmaceúticosource ↗
- PFASsource ↗
Frequently asked
How many EU lobbying meetings has AstraZeneca PLC disclosed?
AstraZeneca PLC (EU Transparency Register no. 249402638316-62) appears in 69 disclosed meetings with EU officials and MEPs between 2024-10-01 and 2026-06-29: 17 with the European Commission and 52 with Members of the European Parliament.
What does AstraZeneca PLC lobby on?
AstraZeneca PLC's disclosed EU meetings most often concern Health, Technology, Trade, Climate. Every meeting and its topic is listed with its official source on this page.
Who does AstraZeneca PLC meet in Brussels?
Across its disclosed meetings, AstraZeneca PLC has met Commission officials including Laszlo Kristoffy, Patricia Reilly, Jana Dabbelt, and MEPs including POLFJÄRD Jessica, SOKOL Tomislav, CIFROVÁ OSTRIHOŇOVÁ Veronika. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with AstraZeneca PLC — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.